PriceTargets.com logo

Life Science REIT - LABS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 114
  • Forecasted Upside: 53.63%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 74.20 As of 06/5/2023 05:40 PM ET
▲ +0.203 (0.27%)

This chart shows the closing price for LABS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Life Science REIT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LABS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LABS

Analyst Price Target is GBX 114
▲ +53.63% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Life Science REIT in the last 3 months. The average price target is GBX 114, with a high forecast of GBX 114 and a low forecast of GBX 114. The average price target represents a 53.63% upside from the last price of GBX 74.20.

This chart shows the closing price for LABS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Life Science REIT.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/6/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/27/2023Jefferies Financial GroupReiterated RatingBuyGBX 114
(Data available from 6/5/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Life Science REIT

Read More

Today's Range

Now: GBX 74.20
Low: 73.60
High: 75.20

50 Day Range

MA: GBX 67.91
Low: 58
High: 75.40

52 Week Range

Now: GBX 74.20
Low: 58
High: 100.50

Volume

385,373 shs

Average Volume

838,757 shs

Market Capitalization

£259.71 million

P/E Ratio

N/A

Dividend Yield

6.06%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Life Science REIT?

The following Wall Street research analysts have issued reports on Life Science REIT in the last year: Jefferies Financial Group Inc..
View the latest analyst ratings for LABS.

What is the current price target for Life Science REIT?

1 Wall Street analysts have set twelve-month price targets for Life Science REIT in the last year. Their average twelve-month price target is GBX 114, suggesting a possible upside of 53.6%. Jefferies Financial Group Inc. has the highest price target set, predicting LABS will reach GBX 114 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of GBX 114 for Life Science REIT in the next year.
View the latest price targets for LABS.

What is the current consensus analyst rating for Life Science REIT?

Life Science REIT currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LABS will outperform the market and that investors should add to their positions of Life Science REIT.
View the latest ratings for LABS.